



FORTIS HEALTHCARE LIMITED

CIN: L85110DL1996PLC076704

Registered Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi-110025

Tel.: +91-11-4713 5000/2682 5000, **Fax:** +91-11-2682 5013

Email: secretarial@fortishealthcare.com, **Website:** www.fortishealthcare.com

NOTICE

Notice is hereby given that the **Nineteenth Annual General Meeting** of **Fortis Healthcare Limited** will be held on Wednesday, **23rd September, 2015 at 12:00 Noon** at **PHD Chamber of Commerce and Industry, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi – 110016**, to transact the following business:

ORDINARY BUSINESS

1. To consider and adopt the Audited Standalone Financial Statements of the Company together with Reports of the Board and Auditors thereon and the Audited Consolidated Financial Statements of the Company including Auditors' Report thereon.
2. To appoint a director in place of Mr. Harpal Singh (DIN-00078224), who retires by rotation and being eligible offers himself for re-appointment.
3. To appoint Auditors and to fix their remuneration and in this regard to consider and if thought fit, to pass, the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions, if any, of the Companies Act, 2013, read with rules made thereunder, M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (Registration No. 117366W/W-100018), be and are hereby appointed as Statutory Auditors of the Company for a period of 5 years, subject to ratification of the appointment by the Members of the Company at every Annual General Meeting as per the provisions of the Companies Act, 2013, at such remuneration plus service tax, out-of-pocket, travelling expenses, etc., as may be mutually agreed between the Board of Directors of the Company and the Auditors.”

SPECIAL BUSINESS

4. To consider and if thought fit, to pass, the following resolution as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 196 and 197 read with Schedule V and the Rules made thereunder and other applicable provisions, if any, of Companies Act, 2013, (hereinafter referred to as “the Act”) (including any statutory modification or re-enactment thereof, for the time being in force) and of Articles of Association of the Company and further subject to the approval of the Central Government, if any, and all other applicable regulatory and other approvals, consents and permissions as may be necessary in this regard and to such conditions as may be imposed by any authority while granting such approval(s), consent(s) and permission(s) and as may be agreed to by the Board of Directors of the

Company (which term shall be deemed to include any Committee thereof which may have been constituted or may hereinafter be constituted by the Board of Directors of the Company, or any director/officer authorized by the Board of Directors/Committee for this purpose), the approval of the Members of the Company be and is hereby accorded to re-appoint Mr. Malvinder Mohan Singh (DIN: 00042981), as Whole-time Director of the Company, designated as “Executive Chairman”, with effect from April 1, 2016 for a period of 3 (three) years, not liable to retire by rotation, on the following terms and conditions:-

- A. Total Remuneration: 5% of Net Profits or ₹ 15,00,00,000 (₹ Fifteen Crores only) per annum, whichever is higher, with the authority granted to the Board of Directors to determine the total remuneration as recommended by the Nomination and Remuneration Committee and revise it from time to time within the limits stipulated in this Resolution.

Besides the above, Mr. Malvinder Mohan Singh shall also be entitled to the following facilities which shall not be included in the computation of ceiling on total remuneration subject to the provisions of the Act and Company's Policy in this regard from time to time:

- i. Provision of Company maintained Car(s) along with chauffeur;
- ii. Telephone and other communication facilities at residence;
- iii. Hospitalization and Accident Insurance as per the policy of the Company;
- iv. Encashment of Earned Leave at the end of the tenure;
- v. Entitlement for travel (Class / Mode) shall be as per the Company Policy from time to time, expenses for which will be borne by the Company on actual cost basis.

Apart from the above, Mr. Singh shall be entitled to reimbursement of any other business related expenses on actual cost basis.

The value of Allowances & Perquisites shall be taken as per Income Tax Rules, wherever applicable. In the absence of any applicable rules, the Allowances & Perquisites shall be valued at actual cost.

In addition to the above, Mr. Singh will also be entitled to the following benefits as per the policy/rules of the Company in force from time to time:

- i. Company's contribution to Provident Fund;
- ii. Payment of Gratuity and other retirement benefits

and these may not be included in the computation of ceiling on total remuneration to the extent these either singly or put together are not taxable under the Income Tax Act, 1961.

Notwithstanding anything herein above and subject to the terms of the approval of the Ministry of Corporate Affairs, Central Government, where in any financial year during the currency of tenure of Mr. Malvinder Mohan Singh, the Company has no profits or its profits are inadequate, the Company shall pay to Mr. Singh ₹ 15 crores or such remuneration as may be decided by Nomination and Remuneration Committee within the said limit, as minimum remuneration.

Sitting Fee:

He shall not be paid any sitting fee for attending Meetings of the Board and/or any of its Committee(s).

General:

He shall be eligible for other facilities and benefits etc. as per rules of the Company from time to time. He shall be subject to the other service conditions, rules and regulations of the Company from time to time.

- B. Subject to the superintendence, control and direction of the Board, Mr. Malvinder Mohan Singh shall perform such duties and functions as would be commensurate with his position as Executive Chairman of the Company and as may be delegated to him by the Board from time to time.

RESOLVED FURTHER THAT Board of Directors on the recommendation of Nomination and Remuneration Committee, may pay remuneration to Mr. Malvinder Mohan Singh, exceeding the aforesaid limits, provided that total remuneration paid to all Executive Directors taken together shall not exceed 10% of the Net Profits of the Company calculated in accordance with the provisions of Section 198 of Companies Act, 2013.

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to do all such acts, deeds and things and to sign, execute and file and/or modify or withdraw all such applications, forms, papers and documents as may be considered necessary or expedient including appointing attorney(s) or authorized representatives, to give effect to this Resolution."

5. To consider and if thought fit, to pass, the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to provision of Sections 196 and 197 read with Schedule V and the Rules made thereunder and other applicable provisions, if any, of Companies Act 2013 (hereinafter referred to as "the Act") (including any statutory modification or re-enactment thereof, for the time being in force) and of Articles of

Association of the Company and further subject to the approval of the Central Government, if any, and all other applicable regulatory approvals, consents and permissions as may be necessary in this regard and to such conditions as may be imposed by any authority while granting such approval(s), consent(s) and permission(s) and as may be agreed to by the Board of Directors of the Company (which term shall be deemed to include any Committee thereof which may have been constituted or may hereinafter be constituted by the Board of Directors of the Company, or any director/officer authorized by the Board of Directors/ Committee for this purpose), the approval of the Members of the Company be and is hereby accorded to re-appoint Mr. Shivinder Mohan Singh (DIN: 00042910), as Managing Director of the Company, designated as "Executive Vice Chairman" of the Company, for a period of 3 (three) years, w.e.f. November 13, 2015 not liable to retire by rotation, on the following terms and conditions:

- A. Total Remuneration: 5% of Net Profits or ₹ 15,00,00,000 (₹ Fifteen Crores only) per annum, whichever is higher, with the authority granted to the Board of Directors to determine the total remuneration as recommended by the Nomination and Remuneration Committee and revise it from time to time within the limits stipulated in this Resolution.

Besides the above, Mr. Shivinder Mohan Singh shall also be entitled to the following facilities which shall not be included in the computation of ceiling on total remuneration subject to the provisions of the Act and Company's policy in this regard from time to time:

- i. Provision of Company maintained Car(s) along with chauffeur;
- ii. Telephone and other communication facilities at residence;
- iii. Hospitalization and Accident Insurance as per the policy of the Company;
- iv. Encashment of Earned Leave at the end of the tenure;
- v. Entitlement for travel (Class/ Mode) shall be as per the Company Policy from time to time, expenses for which will be borne by the Company on actual cost basis.

Apart from the above, Mr. Singh shall be entitled to reimbursement of any other business related expenses on actual cost basis.

The value of Allowances & Perquisites shall be taken as per Income Tax Rules, wherever applicable. In the absence of any applicable rules, the Allowances & Perquisites shall be valued at actual cost.

In addition to the above, Mr. Singh will also be entitled to the following benefits as per the policy/ rules of the Company in force from time to time:

- i. Company's contribution to Provident Fund;
- ii. Payment of Gratuity and other retirement benefits

and these may not be included in the computation of ceiling on total remuneration to the extent these either singly or put together are not taxable under the Income Tax Act, 1961.

Notwithstanding anything herein above and subject to the terms of the approval of the Ministry of Corporate Affairs, Central Government, where in any financial year during the currency of tenure of Mr. Shivinder Mohan Singh, the Company has no profits or its profits are inadequate, the Company shall pay to Mr. Singh ₹ 15 crores or such remuneration as may be decided by Nomination and Remuneration Committee within the said limit, as minimum remuneration.

Sitting Fee:

He shall not be paid any sitting fee for attending Meetings of the Board and/or any of its Committee(s).

General:

He shall be eligible for other facilities and benefits etc. as per rules of the Company from time to time. He shall be subject to the other service conditions, rules and regulations of the Company from time to time.

- B. Subject to the superintendence, control and direction of the Board, Mr. Shivinder Mohan Singh shall perform such duties and functions as would be commensurate with his position as Executive Vice Chairman of the Company and as may be delegated to him by the Board from time to time.

RESOLVED FURTHER THAT Board of Directors on the recommendation of Nomination and Remuneration Committee, may pay remuneration to Mr. Shivinder Mohan Singh, exceeding the aforesaid limits, provided that total remuneration paid to all Executive Directors taken together shall not exceed 10% of the Net Profits of the Company calculated in accordance with the provisions of Section 198 of Companies Act, 2013.

RESOLVED FURTHER THAT the Board of Directors of the Company be and are hereby authorized to do all such acts, deeds and things and to sign, execute and file and/or modify or withdraw all such applications, forms, papers and documents as may be considered necessary or expedient including appointing attorney(s) or authorised representatives to give effect to this Resolution.”

6. To consider and if thought fit, to pass the following resolution as a **Special Resolution**:

“**RESOLVED THAT** in supersession of the resolutions passed by the Members at its meetings held on September 19, 2011, September 29, 2012 and September 24, 2014, in this regard, and pursuant to the provisions of Sections 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 and Rules made thereunder and Article 87 of the Articles of Association, the Company be and is hereby authorised to pay Honorarium to its Non-Executive Directors (other than Nominee Director(s)), for

the time being on the Board of the Company and who may be appointed in such position hereinafter, for a period of five years commencing from April 1, 2015, not exceeding 1% (one percent) or such other percentage of the Net Profits of the Company in any financial year as may be specified under the Companies Act, 2013 from time to time and computed in the manner provided under Section 198 of the Companies Act, 2013.

RESOLVED FURTHER THAT the above remuneration shall be in addition to fees payable to the director for attending the meetings of the Board or Committee thereof.

RESOLVED FURTHER THAT the Board of Directors of the Company (including Nomination and Remuneration Committee) be and is hereby authorized to do all such acts and to take all steps as may be necessary, proper or expedient to give effect to this resolution.”

7. To consider and if thought fit, to pass, the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), remuneration of ₹ 2.30 lacs plus out of pocket expenses and taxes, being paid to M/s. Jitender, Navneet & Co., Cost Auditors appointed by the Board of Directors, to conduct the audit of the cost records of the Company, for the Financial Year ended March 31, 2015, be and is hereby ratified and confirmed.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

8. To consider and if thought fit, to pass, the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 181 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Board of Directors of the Company be and is hereby authorized to contribute, in any financial year, charitable and other bonafide funds, any amounts the aggregate of which, may exceed five per cent of its average net profits for the three immediately preceding financial years, subject to a limit of ₹ 5 Crore.”

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

**By Order of the Board
For Fortis Healthcare Limited**

Sd/-

**Rahul Ranjan
Company Secretary**

**Date : August 6, 2015
Place : Gurgaon**

NOTES:

1. The Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013, is enclosed herewith and forms part of this Notice.
2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY(IES) TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND SUCH PROXY(IES) NEED NOT BE A MEMBER OF THE COMPANY.** Proxies, to be effective shall be duly filled, stamped, signed and deposited, not less than 48 hours before the commencement of the Meeting at the Registered Office of the Company.

Pursuant to the provisions of Companies Act, 2013 and the rules thereunder, a person can act as proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the company carrying voting rights. A member holding more than ten percent, of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as proxy for any other person or shareholder.
3. Pursuant to provisions of Clause 49 of the Listing Agreement, the particulars of Directors seeking appointment/ re-appointment/ Change in remuneration at this Annual General Meeting are annexed to the Notice.
4. The Register of Members and Share Transfer Books of the Company shall remain closed from Wednesday, 16th day of September, 2015 to Wednesday, 23rd day of September, 2015, both days inclusive. The cut-off date for the purpose of remote e-voting and for physical voting is Wednesday, September 16, 2015. The E-voting facility will be available from 9:00 am on September 20, 2015 to 5:00 pm on September 22, 2015 after which the e-voting facility will not be available.
5. Members are requested to bring their copy of Annual Report to the Meeting.
6. Members / Proxies are requested to bring the Attendance Slip/proxy form duly filled in, sent herewith alongwith the notice of the AGM at the meeting. The members who hold shares in dematerialized form are requested to bring their Client Master List / Depository Participant Statement/ Delivery Instruction Slip reflecting their Client Id. and DP Id. No. for easier identification of attendance at the meeting.
7. Members are requested to notify any change of address:
 - a. to their depository participants in respect of shares held in dematerialized form, and
 - b. to Company/Registrar and Transfer Agent ("Karvy") in respect of shares in physical form, under their signatures and quoting folio number (including for change of residential status/e-mail id, bank details, etc.).
8. In case of joint holders attending the meeting, only such joint holder whose name appears at the top in the hierarchy of names shall be entitled to vote.
9. Corporate members are requested to send a duly certified copy of the Board Resolution/Power of Attorney authorizing their representative to attend and vote at the Annual General Meeting.
10. For security reasons, no article/baggage will be allowed at the venue of the meeting. The members/attendees are strictly requested not to bring any article/baggage, etc. at the venue of the meeting.
11. Those members who have not yet got their Equity Shares dematerialized, are requested to contact any of the Depository Participants in their vicinity for getting their shares dematerialized.
12. Members may avail the nomination facility as provided under Section 72 of the Companies Act, 2013.
13. Non-Resident Indian Members are requested to inform Karvy, immediately of:
 - (a) Change in their residential status on return to India for permanent settlement, and
 - (b) Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.
14. Members desiring any information as regards the Accounts are requested to write to the Company Secretary, giving at least 7 days notice prior to the date of Annual General Meeting to enable the Management to reply at the Meeting.
15. The notice of Annual General Meeting will be sent to those members / beneficial owners whose name will appear in the register of members / list of beneficiaries received from the depositories as on Friday, August 14, 2015. A person who is not a members as on the cut-off date i.e. September 16, 2015, should treat this Notice for information purposes only.
16. The Ministry of Corporate Affairs has undertaken a 'Green Initiative in the Corporate Governance' by allowing paperless compliances by Companies. Also, the Listing Agreement with the Stock Exchange(s) permits Companies to send soft copies of the Annual Report to all those shareholders who have registered their email address for the said purpose. Members are requested to support this Green Initiative by registering/updating their e-mail address for receiving electronic communications. The notice for Annual General Meeting alongwith the annual report of the Company will be made available on the Company's website- www.fortishealthcare.com
17. Pursuant to Sections 205A and 205C of the Companies Act, 1956 and/ or Section 123 of the Companies Act, 2013 and other applicable provisions, if any, all unclaimed/ unpaid application money remaining unclaimed/unpaid for a period of seven years from the date they became due for payment, in relation to the Company, have been transferred to the Investor Education and Protection Fund (IEPF) established by the Central Government. No claim shall lie against the IEPF or the Company for the amounts so transferred nor shall any payment be made in respect of such claim.

18. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN to the Company /Karvy.
19. Members who have not registered their e-mail addresses so far are requested to register their e-mail address for receiving all communication including Annual Report, Notices, Circulars, etc. from the Company electronically.
20. Electronic copy of the Notice of the 19th Annual General Meeting of the Company is being sent to all members whose email IDs are registered with the Company/ Depository Participants for communication purposes unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copy of the Notice is being sent in the permitted mode.
21. The Register of Directors and Key Managerial Personnel and their shareholding, Register of Contracts or Arrangements in which Directors are interested and all documents referred to in the Notice and Explanatory Statement will be available for inspection at the Company's registered office during normal business hours on the working days upto the date of Annual General Meeting.
22. In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (substituted by Companies (Management and Administration) Amendment Rules, 2015) and other applicable provisions, if any, of Companies Act, 2013 and Clause 35B of the Listing Agreement, the assent or dissent of the shareholders in respect of the resolutions contained in the Annual General Meeting Notice is also being taken through e-voting facility provided through Karvy Computershare Private Limited.
23. The e-voting event number, User Id and Password along with the detailed instructions for remote e-voting are provided in the notice of remote e-voting, being sent along with the Notice of Annual General Meeting.
24. The result on resolutions shall be declared on or before closing business hours on Thursday, September 24, 2015 at the registered office of the Company and the same along with the scrutinizer's report shall also be available on the website of the Company and on the website of Karvy Computershare Private Limited.
25. The Route Map for the 19th Annual General Meeting of the Company alongwith the Landmark forms part of this Report.
26. The shareholders can opt for only one mode of voting i.e. remote e-voting or physical polling at the meeting. In case of voting by both the modes, vote casted through remote e-voting will be considered final and voting through physical ballot will not be considered. The members who have cast their vote by remote e-voting may also attend the Meeting.

EXPLANATORY STATEMENT

(Pursuant to Section 102(1) of the Companies Act, 2013)

Item No. 3

This explanatory statement is provided though strictly not required as per section 102 of the Companies Act, 2013.

The Companies Act, 2013 has introduced the concept of rotation of auditors. It states that no listed Company shall appoint or re-appoint an audit firm as auditor for more than two terms of five consecutive years (total 10 years). Further, an audit firm which has completed its term as aforesaid shall not be eligible for re-appointment as auditor in the same company for 5 years from completion of such term. The Companies Act, 2013 also allows a transition period of three years for complying with above.

M/s. S. R. Batliboi & Co. LLP, Chartered Accountants are the statutory auditors of the Company for the Financial Year 2000-01 and onwards. Since they have been the statutory auditors for a period of more than 10 years, it is mandatory for rotation of the auditors as per the Companies Act, 2013.

The provisions of the Companies Act, 2013 on transition of Auditors allow continuing with the current auditors for a period of 3 more years i.e. till March, 2017. However, the Shareholders based on the recommendation of Audit & Risk Management Committee and Board of Directors have in the last Annual General Meeting decided, that the tenure of current auditors be restricted to 1 year only and thus it is proposed to change the statutory auditors of the Company for Financial Year 2015-16 onwards.

The Board of Directors recommends to appoint M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, as Statutory Auditors of the Company for a period of 5 (Five) years commencing from Financial Year 2015-16, subject to ratification by members at each Annual General Meeting.

None of the Directors/ Key Managerial Personnel or their relatives are in any ways concerned or interested, financially or otherwise, in the proposed resolution.

Item No. 4

Mr. Malvinder Mohan Singh, one of the promoter Directors of the Company, was appointed as a Whole-Time Director of the Company, designated as the Executive Chairman for a period of 5 years w.e.f. January 11, 2012, not drawing any remuneration, subject to the approval of the Central Government. Further, the Board of Directors had, at its meeting held on March 26, 2013, approved the variation to the terms of his appointment including payment of remuneration for a period of three years w.e.f. April 1, 2013 subject to the approval of the Central Government under Sections 196 and 197 read with Schedule V to Companies Act, 2013 (hereinafter referred to "the Act").

However, the said approval was in line with the provisions of Companies Act, 1956 and in view of the enactment of Companies Act, 2013, effective April 1, 2014, the terms of appointment of Mr. Malvinder Mohan Singh for payment of remuneration for the remaining period (i.e. April 1, 2014 to March 31, 2016) was approved by the shareholders through Postal Ballot on December 29, 2014, in accordance with the provisions laid down under the Act.

In view of the above, the tenure of appointment of Mr. Malvinder Mohan Singh will expire on March 31, 2016. On recommendation of the Nomination and Remuneration Committee, in recognition of the valuable services rendered by Mr. Singh, the Board of Directors had, in its meeting held on August 6, 2015, re-appointed him as Whole-time Director, designated as the “Executive Chairman” for further period of 3 years w.e.f. April 1, 2016, subject to the approval of shareholders of the Company and the Central Government under Sections 196 and 197 read with Schedule V of the Act.

It may please be noted that:

- No Stock Options have been granted to Mr. Singh under “Employee Stock Options Plan-2007” and “Employee Stock Options Plan - 2011” of the Company.
- No severance fees is payable to Mr. Singh in case of termination of his appointment by the Company.

It is proposed to re-appoint Mr. Singh for a period of three years effective April 1, 2016 at a remuneration as detailed out in Item No. 4.

The above may be treated as written memorandum setting out the terms of re-appointment of Mr. Malvinder Mohan Singh under section 190 of the Companies Act, 2013.

The Board of Directors commends the resolution as set out at Item No. 4 for the approval of the Members as Special Resolution.

None of the Directors or Key Managerial Personnel of the Company or their relative except Mr. Shivinder Mohan Singh and Mr. Harpal Singh (being related to Mr. Malvinder Mohan Singh) and Mr. Malvinder Mohan Singh himself, is/are in any way, concerned or interested, financial or otherwise, in the proposed resolution except to the extent of their respective shareholding in the Company, if any.

The additional information as required by Schedule V to the Act is given below:

I. General Information

- (i) **Nature of Industry:** Business of providing healthcare services and running multi-specialty hospitals.
- (ii) **Date or expected date of commencement of commercial production:** The Company was incorporated on February 28, 1996.
- (iii) **In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:** NOT APPLICABLE
- (iv) **Financial performance (on standalone basis) based on given indicators as per Audited Financial Results for the year ended March 31, 2015:**

(Amount in ₹ lacs)

Particulars	For the year ended 31.03.2015 (Audited)
*Turnover and other income	82855.23
*Net profit after tax	(3655.97)

*Excluding Exceptional Items

- (v) **Foreign investments or collaborations, if any:** NOT APPLICABLE.

II. Information about the appointee

(i) Experience and Background details:

Mr. Malvinder Mohan Singh, aged 42 years, earned his MBA from the Fuqua School of Business, Duke University, USA, and is an honors graduate in Economics. He is an accomplished industry leader and is widely recognized nationally and internationally as a flag-bearer of Indian business.

Malvinder incubated and established Fortis Healthcare Limited, in the early 2000's. Since then, he has assiduously transformed it into a leading healthcare delivery organization. Malvinder was instrumental in Fortis acquiring significant interests in Parkway, Asia Pacific's largest integrated healthcare company, and was its Chairman during the time. He also spearheaded Fortis' rapid growth through acquisitions in and outside India and the subsequent profitable divestment of its major international assets, to focus on its India hospitals and diagnostics business.

Recognizing the early need and the growing demand for high quality diagnostic services, Malvinder, a decade ago, had the foresight to nurture and build SRL, a company that is today highly regarded amongst the largest providers of comprehensive pathology, radiology and wellness services in the country. Over the years, SRL has introduced a number of high end diagnostic tests that were hitherto unavailable in India and continues to aggressively add to its ever-expanding repertoire and portfolio.

In the Financial Services and Insurance sectors, Malvinder has business interests through Religare Enterprises. He continues to be the majority shareholder in the company, but stepped down from the Board, in 2010, letting the professional management team and a professional Board run the organization.

Previously, Malvinder was Chairman, MD and CEO of Ranbaxy Laboratories. He led the expansion of Ranbaxy through a series of strategic partnerships and acquisitions resulting in Ranbaxy becoming a top 10 generic pharmaceutical company, globally. Later, he was instrumental in the coming together of Ranbaxy and Daiichi Sankyo, to create the world's fifteenth largest pharmaceutical company – a move seen as a game-changer by industry experts.

Malvinder supports a number of voluntary organizations, foundations and trusts who are doing path breaking work in rendering community service with a focus on curative and preventive health. He is a Trustee on the Fortis Foundation and a Patron of 'Nanhi Chhaan and 'Save the Children India'. He has also championed the cause of human dignity in India and is the Country Chair for 'Global Dignity', an autonomous non-profit organization.

Malvinder is a member of the Board of Visitors at the

Fuqua School of Business (Duke University, USA) and is on the Board of the Indian Council for Research on International Economic Relations (ICRIER). He is the Chairman for the National Council For Services, at CII (2013 Onwards), the Premier Industry Association, in India.

He is widely regarded for his business acumen and his acute understanding of the global and Indian economy as much as he is for his demonstrated ability to steer companies always keeping in mind the best interests of its stakeholders.

(ii) Past remuneration drawn:

During the Financial Year 2014-15, the remuneration drawn by Mr. Malvinder Mohan Singh subject to approval of Central Government, was as follows:

(Amount in ₹ Crore)

Salary	Perquisites and allowances	Commission, bonus and performance Linked incentive	Retiral Benefits	Others	Total cost to the Company
5.22	0	0	0	0.10	5.32

(iii) Recognition and Awards/Achievements:

- Businessman of the year – World Sikh Awards, London (2014)
- Outstanding Entrepreneurship Award (2014)- Enterprise Asia
- Emerging Business Leaders of the Year Award (2012)- AIMA
- Indian Business Leader of the Year (2010)- NDTV
- Dynamic Entrepreneur of the year (2009) – Pharma Leadership Summit and Awards
- Ten People to watch in 2009 – Business World
- Business Man of the Year 2008 – Financial Chronicle
- Pharma 40 (2008) – World Pharmaceutical Frontiers Survey
- Golden Peacock Award for Business Leadership (2008)
- Amity Leadership Award (2008) - Amity Foundation
- Most Consistent Wealth Creator (2006) – Leading Brokerage Motilal Oswal
- India Business Leadership Award (2006) – CNBC TV18
- Pharma Excellence Award for leveraging Global Opportunity (2006) - Express Pharma
- Most Promising Young Corporate Leader (2006)
- Rajiv Gandhi Award (2005)
- Delhi Ratna Award (2005) - PHDCCI
- Udyog Ratna (2005) - PHDCCI

- Board and the Management
- Providing strategic direction and guidance to the Board and the Senior Management of the company
 - Overseeing Risk Management and Governance Frameworks across the organization
 - Driving compliance to highest standards of Corporate Governance
 - Driving the Vision, Mission, Values and Culture of the organization
 - Assessing and ensuring that the Right Top Management Team is in place
 - Strategic guidance in matters of longer-term growth strategy
 - Reviewing Annual Operating Plans / Budgets & Operational & Financial business performance
 - Overseeing significant Capital Structure decisions of the company
 - Anchoring relationships with External Stakeholders
 - Championing Innovation and Technology-led disruptions in the business model
 - Representing the company on Policy matters with Government / Regulators
 - Overseeing the Corporate Social Responsibility Framework and Programs

Malvinder is widely acknowledged as an international business leader and is known for his business acumen and strong leadership capabilities in shaping, guiding and leading large organisations in complex global environments. He has in-depth knowledge and experience in the healthcare sector.

(iv) Job profile and suitability:

As the Executive Chairman of the Company, he is responsible for the following activities:

- Ensuring effective and efficient Board Management
- Ensuring alignment between the Shareholders,

The company has made consistent progress under his Chairmanship and he has been instrumental in successfully establishing the Fortis Brand as synonymous with quality Healthcare and service excellence. Under his guidance, the organization has successfully become a leading national healthcare player, created an asset light business model, delevered

its balance sheet, exited International businesses, enhanced focus on India, increased operational performance of India business, brought greater focus on Clinical Excellence and Patient Centricity and has successfully grown SRL into the leading national diagnostics player.

(v) Remuneration proposed:

5% of Net Profits or ₹ 15,00,00,000 (₹ Fifteen Crores only) per annum, whichever is higher, with the authority granted to the Board of Directors to determine the total remuneration as recommended by the Nomination and Remuneration Committee and revise it from time to time within the limits stipulated in this Resolution. Further, the Board of Directors on the recommendation of Nomination and Remuneration Committee, may pay remuneration to Mr. Malvinder Mohan Singh, exceeding the aforesaid limits, provided that total remuneration paid to all Executive Directors taken together shall not exceed 10% of Net Profits of the Company calculated in accordance with the provisions of Section 198 of Companies Act, 2013.

(vi) Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person:

The proposed remuneration of Mr. Malvinder Mohan Singh, who is a professional, possessing invaluable and rich knowledge, experience and insights complemented with the vast business experience, is comparable with Executive Directors of other Companies and is in parity with the Industry Standards for such a responsible position.

(vii) Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any:

Mr. Malvinder Mohan Singh directly holds 11,508 Equity Shares of the Company and being one of the promoters of the Company, indirectly (alongwith his relatives) holds 71.34% of the paid up capital. He is also related to Mr. Shivinder Mohan Singh, Executive Vice Chairman and Mr. Harpal Singh. Except proposed remuneration as stated above, Mr. Malvinder Mohan Singh does not have any other pecuniary relationship with the Company and its managerial personnel.

(viii) Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Malvinder Mohan Singh holds Directorships:

S. No.	Name of the Company
1	Oscar Investments Limited
2	SRL Limited
3	Fortis Clinical Research Limited
4	Ligare Voyages Limited
5	Luxury Farms Private Limited
6	Malav Holdings Private Limited

S. No.	Name of the Company
7	Fortis Healthcare Holdings Private Limited
8	Vistas Realtors Private Limited
9	Vistas Complexes Private Limited
10	RHC Holding Private Limited
11	RHC Finance Private Limited
12	Shimal Healthcare Private Limited

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No.	Name of Company	Name of Committee	Designation (Chairman/Member)
1	Oscar Investments Limited	Audit Committee	Member
2	Limited	Stakeholder Relationship Committee	Member

*Includes only Audit Committee and Shareholder's/ Investor Grievance Committee

Shareholding in the Company: 11508 equity shares of ₹ 10 each (direct).

Original date of appointment: August 12, 1999

During the Financial Year 2014-15, Mr. Singh has attended 5 Board Meetings of the Company (Out of Six held during the year).

III. Other information:

(i) Reasons for loss or inadequate profits:

During the Financial Year 2014-15, the Company posted a Net loss of Rs. 33.91 Crores as against a Net Profit of Rs. 23.99 Crores during Financial Year 2013-14.

The profitability of the Company (FHL) is dependent upon the following factors:

Healthcare facilities have a longer gestation period due to the capital intensive nature of the business. In the start-up phase a facility shows muted profitability as initial volumes are low and operating leverage is yet to be captured. As the facility matures with higher occupancies and volumes, operations begin to stabilize and as a result profitability improves. The Companies new facilities are progressively showing better performance as they ramp up.

The Company has historically followed an aggressive growth strategy in order to reach a certain size and scale and gain a pan-India footprint. This fast paced growth resulted in profit margin being under pressure. Going forward the Company expects to expand in a calibrated manner using its asset light strategy and expects to better utilize its existing infrastructure and assets and further strengthen its processes and systems to increase efficiency and improve profitability.

(ii) **Steps taken or proposed to be taken for improvement:**

The Company focusses on providing tertiary and quaternary care healthcare services and has implemented its strategy to strengthen its key pillars under the “Lakhya” program. This pan – Fortis initiative strives to achieve excellence on the 5 core pillars of (1) Patient Centricity (2) Clinical Excellence (3) Community Connect (4) Talent Engagement (5) Investor Confidence that will drive the organization forward in the coming years.

The Company has further strengthened its focus on the India market and completed the last of its international divestments. The Company expects that as its existing facilities further ramp up led by improving occupancies, an increasing ARPOB a result of a better product mix and lower ALOS, the performance of the Company will progressively show a healthier picture. New facilities have shown an encouraging start and are expected to stabilize at the earliest and start contributing to profitability.

The Companies expansion strategy will be primarily organic in nature for the next few years will involve minimal capital expenditure as it plans to expand primarily through brownfield expansion i.e. expansion in existing facilities. A larger part of this expansion will entail investments by the Religare Health Trust in line with the Company’s asset light growth strategy. This will result in faster profitability as gestation periods will be significantly shorter and involve lesser initial costs. The Company does not foresee starting any new greenfield projects nor undertaking any acquisitions.

The Company continues to undertake a series of initiatives in order to further expand and strengthen its medical programs. In the year gone by it launched a number of medical specialties and treatment options in the field of oncology, gastroenterology and hepatobiliary sciences, dermatology, cosmetology and wellness. It commissioned an orthopedic and spine super specialty center, a center for Heart failure management and heart transplant and a center for sports orthopaedics and arthroscopy. All these new medical programs and centers with state of the art treatment options will further bolster the product mix, attract higher patient volumes at the Companies facilities and improve performance.

The Company strives to maximise efficiencies through the greater integration of its healthcare facilities through various programs and systems developed for this purpose which include Fortis Operating System (FOS) (a patient management system that seeks to enhance patient care services through the establishment of standardised non-clinical processes) and Central Purchase and Supply Management Program (to improve the procurement methodology and minimise costs associated with the supply chain by implementing standardisation of consumables, medical equipments and other items across facilities).

It has in the year gone by, also implemented and enterprise wide Oracle platform to align selected key functions and streamline processes and systems across the Fortis network.

(iii) **Expected increase in productivity and profits in measurable terms**

(Amount ₹ In Crore)

Years	Turnover	Profit before tax as per Statement of Profit and Loss
2015-16	779.77	(31.62)
2016-17	857.74	(13.16)
2017-18	943.52	(0.30)

IV Disclosures- General disclosures are given under Corporate Governance Report forming part of Board Report.

Item No. 5

Mr. Shivinder Mohan Singh, one of the promoter Directors of the Company, was appointed as the Managing Director of the Company for a period of 3 years w.e.f. November 13, 2012, subject to the approval of the Central Government pursuant to the provisions of Section 269 of the Companies Act, 1956. Subsequently, Central Government has also conferred its approval for the appointment of Mr. Singh as the Managing Director of the Company vide its Letter No. SRN B60101565/4/2012- CL. VII dated October 17, 2013 as per the details summarized below:

Period	Remuneration approved (Amounts in ₹ Crore)
13/11/2012 to 12/11/2013	6.20
13/11/2013 to 12/11/2014	7.13
13/11/2014 to 12/11/2015	8.20
TOTAL	21.53

On the recommendation of the Nomination and Remuneration Committee, in recognition of the valuable services rendered by Mr. Singh, the Board of Directors had, at its meeting held on August 6, 2015, re-appointed him as Managing Director, designated as the “Executive Vice Chairman” for further period of 3 years w.e.f. November 13, 2015, subject to the approval of shareholders of the Company and the Central Government under Sections 196 and 197 read with Schedule V to the Companies Act, 2013 (hereinafter referred to “the Act”).

It may please be noted that:

- No Stock Options have been granted to Mr. Singh under “Employee Stock Options Plan-2007” and “Employee Stock Options Plan - 2011” of the Company.
- No severance fees is payable to Mr. Singh in case of termination of his appointment by the Company.

It is proposed to re-appoint Mr. Singh for a period of three years effective November 13, 2015 at a remuneration as detailed out in Item No. 5

The above may be treated as written memorandum setting out the terms of re-appointment of Mr. Shivinder Mohan Singh under section 190 of the Companies Act, 2013.

The Board of Directors commends the resolution as set out at Item No. 5 for the approval of the Members as Special Resolution.

None of the Directors or Key Managerial Personnel of the Company or their relatives except Mr. Malvinder Mohan Singh (being related to Mr. Shivinder Mohan Singh) and Mr. Shivinder Mohan Singh himself, is/are in any way concerned or interested, financially or otherwise, in the proposed resolution except to the extent of their respective shareholding in the Company, if any.

The additional information as required by Schedule V to the Act is given below:

I. General Information

- (i) **Nature of Industry:** Business of providing healthcare services and running multi-specialty hospitals.
- (ii) **Date or expected date of commencement of commercial production:** The Company was incorporated on February 28, 1996.
- (iii) **In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:** NOT APPLICABLE
- (iv) **Financial performance (on standalone basis) based on given indicators as per Audited Financial Results for the year ended March 31, 2015:**

(Amount ₹ In lac)

Particulars	For the year ended 31.03.2015 (Audited)
*Turnover and other income	82855.23
*Net profit after tax	(3655.97)

*Excluding Exceptional Items

- (v) **Foreign investments or collaborations, if any:** NOT APPLICABLE.

II. Information about the appointee

- (i) **Background details, Experience and Rewards and Recognitions:**

Mr. Shivinder Mohan Singh, aged 40 years, is an entrepreneur who aspires to change the way Healthcare is delivered in India and the world. He is currently the Executive Vice Chairman of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India and is driven by a vision to save and enrich lives through clinical excellence.

In his previous roles, Shivinder, created the foundation of the culture of Fortis by leading the first hospital

- (ii) **Past remuneration drawn:**

During the Financial Year 2014-15, the remuneration drawn by Mr. Shivinder Mohan Singh, in terms of Central Government approval Letter No. SRN B60101565/4/2012- CL. VII dated October 17, 2013 was as follows:

(Amount in ₹ Crore)

Salary	Perquisites and allowances	Commission, bonus and performance Linked incentive	Retiral Benefits	Others	Total cost to the Company
5.22	0	0	0	0.14	5.36

at Mohali as its COO. He also led the development of Fortis through its initial years by conceptualizing its strategy and growth through various Greenfield projects and acquisitions. He was instrumental in the group's effort for the acquisition of Escorts Heart Institute and Research Centre Ltd (EHIRCL) in 2005; Malar Hospital in Chennai in 2008 and the Wockhardt acquisition in 2009. He has conceptualized, designed and built the most modern hospital in India and Asia, the Fortis Memorial Research Institute, a destination hospital in Asia.

Shivinder is also one of the principal promoters of Religare Enterprises Limited and SRL Limited, India's largest diagnostic network.

He is actively involved in many industry bodies and various new initiatives. Shivinder is on the Steering Committee of Federation of Indian Chambers of Commerce and Industry (FICCI). He is a board member of Aspen India and a Governing Council Member of All India Management Association (AIMA). He also chairs FICCI's Committee on Culture and is one of the Founders of NATHEALTH (the Healthcare Federation of India).

Shivinder is on the Advisory Board of AIESEC India, the world's largest student-run organisation and a platform for young people to explore and develop their leadership potential for a positive impact on society.

He was recently nominated as a Young Global Leader 2013 by the World Economic Forum.

Shivinder has done his MBA with specialisation in health sector management from the Duke University Business School, USA. He is an alumnus of Doon School and an Honours Graduate in Mathematics from St. Stephens College, Delhi.

Shivinder is also on the board of visitors of Duke University Business School, Durham, NC, USA.

While healthcare is a passion for Shivinder, his dream is to contribute in building a vibrant India. He is actively involved in initiatives focusing on social change, including the 'Little Hearts' programme, that supports life saving cardiac surgeries to the less privileged children. He is also involved in a number of initiatives that focus on a better future for the girl child and institutionalizing delivery and education.

(iii) Job profile and suitability:

- Works along with the Executive Chairman in ensuring effective operation of the Board and its committees in conformity with the highest standards of corporate governance
- Ensures effective communication with all stakeholders and other relevant constituencies and ensure that the views of these groups are understood by the top management
- Healthcare Specialist and lead on Medical Strategy and Clinical Governance for the group
- Advises the Executive Chairman in the development of strategy, business development and provide support where required
- Leads the infrastructure development of the Company by heading the projects and design division.

Mr. Shivinder Mohan Singh has been shouldering onerous responsibilities and multitude of challenges in overseeing and managing growth (both organic and inorganic) and in synergizing complex operations in an increasingly competitive environment in diverse geographies within the country. Mr. Singh is also providing leadership at the helm of a service organization with people from divergent cultures.

The Company has made consistent progress under the leadership of Mr. Shivinder Mohan Singh, who has successfully established Fortis brand as a synonymous with quality healthcare and service excellence.

His contribution to the Indian Healthcare Scenario is widely acknowledged. His strategy for Fortis and its execution has been recognized by Harvard Business School in the form of a case study. He has been playing an important and active role in shaping the private healthcare space in India. He has also been tirelessly working on getting the private healthcare sector to work closely with the government. He has also worked with leading functionaries within the healthcare sector to set up a national healthcare federation. Shivinder is also keenly involved in various CSR initiatives focused on the girl child, HIV education, providing quality healthcare to rural India, to name a few.

(iv) Remuneration proposed:

5% of Net Profits or ₹ 15,00,00,000 (₹ Fifteen Crores only) per annum, whichever is higher, with the authority granted to the Board of Directors to determine the total remuneration as recommended by the Nomination and Remuneration Committee and revise it from time to time within the limits stipulated in the proposed Resolution. Further, Board of Directors on the recommendation of Nomination and Remuneration Committee, may pay remuneration to Mr. Shivinder Mohan Singh, exceeding the aforesaid limits, provided that total remuneration paid to all Executive Directors taken together shall not exceed

10% of the Net Profits of the Company calculated in accordance with the provisions of Section 198 of the Act.

(v) Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person:

The proposed remuneration of Mr. Shivinder Mohan Singh, who is a professional, possessing invaluable and rich knowledge, experience and insights complemented with the vast business experience, is comparable with Executive Directors of other Companies and is in parity with the Industry Standards for such a responsible position.

(vi) Pecuniary relationship directly or indirectly with the Company or relationship with the managerial personnel, if any:

Mr. Shivinder Mohan Singh is related to Mr. Malvinder Mohan Singh, Executive Chairman and holds 11,508 Equity Shares in the Company and being one of the promoters of the Company, indirectly holds (alongwith his relatives) 71.34% of the paid up capital. Except proposed remuneration as stated above, Mr. Shivinder Mohan Singh does not have any pecuniary relationship with the Company and its managerial personnel.

(vii) Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Shivinder Mohan Singh holds Directorships:

S. No.	Name of the Company
1	Oscar Investments Limited
2	SRL Limited
3	Fortis Clinical Research Limited
4	Ligare Voyages Limited
5	R.C. Nursery Private Limited
6	Fortis Healthcare Holdings Private Limited
7	Greenview Buildtech Private Limited
8	Shivi Holdings Private Limited
9	RHC Holding Private Limited
10	RHC Finance Private Limited
11	Shimal Healthcare Private Limited
12	Uvak Artworks Private Limited

Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies)

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
NIL			

Shareholding in the Company: 11508 equity shares of ₹ 10 each (direct).

Original date of appointment: June 29, 2000

During the Financial Year 2014-15, Mr. Singh has attended all Board Meetings of the Company (Six in number).

III. Other information:

(i) Reasons for loss or inadequate profits:

During the Financial Year 2014-15, the Company posted a Net loss of Rs. 33.91 Crores as against a Net Profit of Rs. 23.99 Crores during Financial Year 2013-14.

The profitability of the Company (FHL) is dependent upon the following factors:

Healthcare facilities have a longer gestation period due to the capital intensive nature of the business. In the start-up phase a facility shows muted profitability as initial volumes are low and operating leverage is yet to be captured. As the facility matures with higher occupancies and volumes, operations begin to stabilize and as a result profitability improves. The Companies new facilities are progressively showing better performance as they ramp up.

The Company has historically followed an aggressive growth strategy in order to reach a certain size and scale and gain a pan-India footprint. This fast paced growth resulted in profit margin being under pressure. Going forward the Company expects to expand in a calibrated manner using its asset light strategy and expects to better utilize its existing infrastructure and assets and further strengthen its processes and systems to increase efficiency and improve profitability.

(ii) Steps taken or proposed to be taken for improvement:

The Company focusses on providing tertiary and quaternary care healthcare services and has implemented its strategy to strengthen its key pillars under the "Lakhya" program. This pan – Fortis initiative strives to achieve excellence on the 5 core pillars of (1) Patient Centricity (2) Clinical Excellence (3) Community Connect (4) Talent Engagement (5) Investor Confidence that will drive the organization forward in the coming years.

The Company has further strengthened its focus on the India market and completed the last of its international divestments. The Company expects that as its existing facilities further ramp up led by improving occupancies, an increasing ARPOB a result of a better product mix and lower ALOS, the performance of the Company will progressively show a healthier picture. New facilities have shown an encouraging start and are expected to stabilize at the earliest and start contributing to profitability.

The Companies expansion strategy will be primarily organic in nature for the next few years will involve minimal capital expenditure as it plans to expand primarily through brownfield expansion i.e. expansion in existing facilities. A larger part of this

expansion will entail investments by the Religare Health Trust in line with the Company's asset light growth strategy. This will result in faster profitability as gestation periods will be significantly shorter and involve lesser initial costs. The Company does not foresee starting any new greenfield projects nor undertaking any acquisitions.

The Company continues to undertake a series of initiatives in order to further expand and strengthen its medical programs. In the year gone by it launched a number of medical specialties and treatment options in the field of oncology, gastroenterology and hepatobiliary sciences, dermatology, cosmetology and wellness. It commissioned an orthopedic and spine super specialty center, a center for Heart failure management and heart transplant and a center for sports orthopaedics and arthroscopy. All these new medical programs and centers with state of the art treatment options will further bolster the product mix, attract higher patient volumes at the Companies facilities and improve performance.

The Company strives to maximise efficiencies through the greater integration of its healthcare facilities through various programs and systems developed for this purpose which include Fortis Operating System (FOS) (a patient management system that seeks to enhance patient care services through the establishment of standardised non-clinical processes) and Central Purchase and Supply Management Program (to improve the procurement methodology and minimise costs associated with the supply chain by implementing standardisation of consumables, medical equipments and other items across facilities). It has in the year gone by, also implemented and enterprise wide Oracle platform to align selected key functions and streamline processes and systems across the Fortis network.

(iii) Expected increase in productivity and profits in measurable terms

(Amount ₹ in Crore)

Years	Turnover	Profit before tax as per Statement of Profit and Loss
2015-16	779.77	(31.62)
2016-17	857.74	(13.16)
2017-18	943.52	(0.30)

IV Disclosures-General disclosures are given under Corporate Governance Report forming part of Board Report.

Item No. 6

The Non-Executive Directors play a very critical and significant role in supporting independent decision making on the Board. The shareholders of the Company had at their meetings held on September 19, 2011, September 29, 2012 and September 24, 2014, *inter-alia*, approved payment of honorarium of ₹ 7.5 lacs per annum to each of the Non-Executive Director of the Company and an additional honorarium of ₹ 2.5 lacs for such director who is a chairman/chairperson of any committee, for a period of five years from April 1, 2011.

In view of the enactment of Companies Act, 2013, it is proposed that total amount to be paid to the Non-Executive Directors (excluding the Nominee Directors) as honorarium in a financial year shall not exceed 1% of the Net Profits calculated under Section 198 of Companies Act, 2013. As per Section 197 of the Companies Act, 2013, the Non-Executive Director may be paid remuneration by way of a monthly, quarterly or annual payment with the prior approval of the Shareholders.

Based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in its meeting held on August 6, 2015, has recommended the aforesaid provision for approval of the members.

The details of the Non-Executive Directors forms part of this Notice.

All the Non-Executive Directors, except Mr. Udai Dhawan, are interested, financially or otherwise in the proposed resolution to the extent of their respective remuneration. Further, Mr. Malvinder Mohan Singh being related to Mr. Harpal Singh, is interested in the proposed resolution to the extent of Mr. Harpal Singh's remuneration. Further, no Key Managerial Personnel and / or relatives of KMP and Directors, except as mentioned before are interested, financially or otherwise, in the proposed resolution.

The Board of Directors commends the resolution as set out at Item No. 6 for the approval of the Members as a Special Resolution.

Item No. 7

The Board of Directors, on the recommendation of the Audit and Risk Management Committee, has approved the appointment and remuneration of the Cost Auditors to conduct the audit of the cost records of the Company, for the Financial Year ended March 31, 2015 as per the following details:

Name of the Cost Audit Firm	Amount (In Rupees)
M/s. Jitender, Navneet & Co.	2.30 lac (plus out of pocket expenses and taxes)

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors as recommended by the Audit and Risk Management Committee and approved by the Board of Directors, has to be ratified by the members of the Company.

Accordingly, consent of the members is sought for ratification of the remuneration payable to the Cost Auditors for the Financial Year ended March 31, 2015.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 7 of the Notice.

The Board of Directors commends the resolution as set out at Item No. 7 for the approval of the Members as an Ordinary Resolution.

Item No. 8

Under Section 181 of the Act, the Board of Directors of the Company may make contributions to charitable and other bonafide funds, provided that prior permission of the Members is

required if such contributions during a financial year exceeds five percent of its average net profits during the three immediately preceding financial years.

The approval of the Members is being sought, pursuant to Section 181 of the Act, for authorizing the Board of Directors of the Company to make contributions to charitable and other funds, in a financial year, exceeding five percent of the Company's average net profits during the three immediately preceding financial years, subject to a limit of ₹ 5 crore.

The Board commends the Ordinary Resolution set out at Item No. 8 of the Notice for approval by the members.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 8 of the Notice.

DETAILS OF DIRECTORS SEEKING APPOINTMENT/RE-APPOINTMENT/CHANGE IN REMUNERATION AT THE ANNUAL GENERAL MEETING

- 1. Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh-** Covered at Item No. 4 and 5, respectively.
- 2. Dr. Brian William Tempest**

Dr. Brian Tempest, aged 68 years, advises Companies, Banks, Investment Funds, Private Equity & High Net Worth Individuals on their Strategy in Asia based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade.

Brian is currently Editor of the Journal of Generic Medicines and a Non Executive Director of the United Nations Medicines Patent Pool in Geneva, Switzerland representing the global generic industry.

Brian started working for Ranbaxy Laboratories in 1995 and he held the positions of Regional Director, President, Managing Director and Chief Executive Officer until 2005 when Ranbaxy became the 9th largest Global Generic Pharmaceutical Company. He then became Chief Mentor, Vice Chairman and Non Executive Director until 2008 when he retired. He is one of the few Westerners to have led a Sensex Nifty 50 Indian blue chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director-Far East and Regional Director-Middle East & Africa from 1985 to 1992.

He has worked in the Pharmaceutical Industry for the last 43 years and has managed Healthcare Businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India and has led many sessions at Investor Meetings held around the world from Tokyo to Las Vegas.

Brian is a Non Executive Director of Religare Capital Markets, SRL Diagnostics Limited, Fortis Healthcare and Glenmark Pharmaceuticals Ltd. Brian speaks at global conferences on the structural changes in the Global Pharmaceutical Marketplace and most of his presentations in the last decade are available on www.briantempest.com.

Brian received a PhD in Chemistry from Lancaster University, UK in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University

Management School. He is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Medicine.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Dr. Brian holds Directorships:

S. No.	Names of the Companies
1	Glenmark Pharmaceuticals Limited
2	Religare Capital Markets Limited
3	SRL Limited
4	Petainer Innopac Packaging Private Limited

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
1	SRL Limited	Audit Committee	Chairman

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: August 2, 2011

Dr. Brian is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Dr. Brian attended all the Board Meetings of the Company (Six in number).

Dr. Brian Tempest is a Non Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Report of Corporate Governance forming part of Annual Report.

3. Mr. Harpal Singh

Mr. Harpal Singh, aged 65 years, is recognized worldwide as a thinker and speaker on the integration of global healthcare. He has a diverse and wide-ranging experience (of over 35 years) in the corporate sector.

Currently he is the Mentor & Chairman Emeritus and a member of the Board of Directors of Fortis Healthcare Limited, Fortis Clinical Research Limited, Religare Enterprises Ltd., and SRL Diagnostics Ltd. He is also Director of Impact Projects Private Ltd and Impact Senior Living Estates Private Limited. He was Non Executive Chairman of India's largest Pharmaceutical Company, Ranbaxy.

He is and has been associated at the Board level with some of India's most renowned schools which include The Doon School, The Scindia School, The Shriram School, The Yadavindra Public Schools and Salwan Public Schools. He was a member of the National Round Table on School Education, a member of the Executive Committee and of the Governing Council of Public Health Foundation of India (PHFI), a member of the Board of the Delhi Red

Cross Society, a member of the Board of Governors of NIIT University, a member of India-UK Round Table and India-US Strategic dialogue. He is a Trustee of Indian National Association for the Club of Rome. He is a Member of the Board of Wadhvani Initiative for Sustainable Health (WISH). He is Founder and Chairman of Nanhi Chhaan Foundation. He was also a member of the Board of Governors of IIT, Indore. Currently he is the Chairman, Save the Children India and Vice Chair, Save the Children International, UK.

An alumnus of The Doon School and an (Hons.) Graduate in Economics from St. Stephens College, New Delhi. A B.S. in Economics and a Masters' in Public Affairs from the California State University at Hayward (C.S.C.H.), California, U.S.A.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Harpal Singh holds Directorships:

S. No.	Names of the Companies
1	SRL Limited
2	Religare Enterprises Limited
3	Fortis Clinical Research Limited
4	Impact Projects Private Limited
5	Impact Agencies Private Limited
6	Impact Senior Living Estates Private Limited

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
1	SRL Limited	Audit Committee	Member

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: 58003 equity shares of ₹ 10 each.

Original date of appointment: August 12, 1999

Mr. Harpal Singh and Mr. Malvinder Mohan Singh are relatives. Mr. Harpal Singh is not related to any other Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Mr. Singh attended all the Board Meetings of the Company (Six in number).

Mr. Harpal Singh is a Non Executive Director, liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

4. Ms. Joji Sekhon Gill

Ms. Joji Sekhon Gill, aged about 50 years, is the Regional Director of Human Resources, Asia Pacific, DuPont. In

this role, she is responsible for talent Strategy for the APAC region. She joined DuPont on August 1, 2012 as the Strategic HR Director for DuPont South Asia.

Prior to this, Joji was the Senior Director for Human Resources for Microsoft India since April 2006. At Microsoft she was responsible for driving the overall people strategy and building synergies for all the six Microsoft businesses in India. Microsoft has more than 6000 full time employees in India.

Joji has more than 25 years of Global HR expertise and has lived and worked in 3 different continents US, Europe and Asia, worked primarily in the US where she spent 15 years.

Joji holds a Bachelor's Degree in Economics and a Masters in Personnel Management and Industrial Relations from Punjab University.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Ms. Gill holds Directorships:

S. No.	Names of the Companies
NIL	

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
NIL			

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: May 28, 2012

Ms. Joji Sekhon Gill is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Ms. Gill attended Four Board Meetings of the Company.

Ms. Joji Gill is a Non Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

5. Ms. Lynette Joy Hepburn Brown

Ms. Lyn Hepburn-Brown, aged 57 years, is an executive leader with over 30 years experience in healthcare, mergers and acquisition, private equity, education, regulatory and nursing services management across Asia Pacific.

She is a former executive manager, chief executive and board member of regulatory authorities, aged care facilities, mental health facilities, public and private hospitals, clinical services, nursing and healthcare agencies in Australia and is presently an Executive and Non-Executive Director for

several organisations across the technology, healthcare, consulting, private equity and memorial sectors.

She holds a Bachelor of Nursing from the University of South Australia and is a past chair of the Australian Nursing and Midwifery Council as well as a past board member of the Nurses Board of South Australia. She is an Adjunct Associate Professor to the Division of Health Sciences of the University of South Australia.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Ms. Lynette holds Directorships:

S. No.	Names of the Companies
NIL	

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
NIL			

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: May 29, 2014

Ms. Lynette is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Ms. Lynette attended five Board Meetings of the Company.

Ms. Lynette is a Non Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

6. Mr. Pradeep Ratilal Raniga

Pradeep Ratilal Raniga, aged 58 years, has rich experience of over 30 years in the fields of accounting, taxation, legal structures, asset protection, financial planning and financing. Currently, he also serves as a Financial Consultant to various companies in Australia, a country to which he migrated in 1985, from South Africa.

Prior to branching out independently, Pradeep was with HLB Mann Judd, Melbourne, rising to Partner and Member of the firm's Executive Committee. Before that he was a Partner at Farrar Jeena & Company, South Africa.

Pradeep has a Bachelors degree in Commerce from the University of Durban Westville, South Africa, and a Post-Graduate Diploma in Accounting from the University of Natal, South Africa. He has qualified as a Chartered Accountant in South Africa and is also a member of the Australian Institute of Chartered Accountants.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Raniga holds Directorships:

S. No.	Names of the Companies
	NIL

*Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
			NIL

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: May 28, 2012

Mr. Raniga is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Mr. Raniga attended Five Board Meetings of the Company.

Mr. Pradeep Raniga is a Non Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

7. Dr. Preetinder Singh Joshi

Dr. Preetinder Singh Joshi, aged 67 years, an eminent Cardiologist, holds an MBBS degree in Medicine from Medical College, Amritsar (Punjab University, Chandigarh 1970) and MD degree in Cardiology & General Medicine from Maulana Azad Medical College (Delhi University 1974). (He stood first in the University and was declared best graduate of Medical College, Amritsar). He became a member of Royal College of Physicians, UK (MRCP) in 1978.

He is a Fellow of American College of Cardiology (FACC), Fellow Royal College of Physicians Edinburgh (FRCP) and Fellow Cardiological Society of India. He has over 40 years of experience in medical profession in India and abroad. He has held many positions of responsibility including Directorship and Head, Department of Medicine & Cardiology Divisions in Escorts Medical Centre (1981-84), Birla Centre for Medical Research, New Delhi (1984-85) & Maharaj Sawan Singh Charitable Hospital, Beas (1985-till date).

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Dr. Joshi holds Directorships:

S. No.	Names of the Companies
1	SRL Limited
2	Escorts Heart Centre Limited
3	Oscar Investments Limited
4	Fortis Hospital Management Limited
5	Fortis Hospitals Limited
6	SRL Diagnostics Private Limited
7	ANR Securities Private Limited
8	AI Book Company Private Limited

*Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
1	SRL Limited	Audit Committee	Member
		Share Allotment and Shareholders'/Investors' Grievance Committee	Member
2	Fortis Hospitals Limited	Audit and Risk Management Committee	Member
3	Oscar Investments Limited	Audit Committee	Member
		Shareholders'/Investors' Grievance and Share Transfer Committee	Chairman
4	SRL Diagnostics Private Limited	Audit Committee	Chairman

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: 33000 equity shares of ₹ 10 each.

Original date of appointment: July 28, 1998

Dr. Joshi is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Dr. Joshi attended all the Board Meetings of the Company (Six in number).

Dr. Joshi is a Non Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

8. Mr. Ravi Umesh Mehrotra

Mr. Ravi Mehrotra, aged 54 years, has over 30 years of experience in the Financial services domain both in India and internationally. He is currently associated with Religare Group. Prior to this, Mr. Mehrotra was associated with PineBridge Investments (erstwhile AIG) where he was the Global Head of Retail & Intermediary Channels. His career span also includes assignments in India as the President of Franklin Templeton Asset Management, CIO of Kothari Pioneer, Executive Vice President & Co-founder of Prime Securities and Vice President of Bank of America in their Investment Banking & Treasury Group.

Mr. Mehrotra graduated from the University of Mumbai with a Bachelor of Commerce. He also received a Post Graduate Diploma in Business Management from the Xavier Labour Relations Institute of Jamshedpur in India.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Mehrotra holds Directorships:

S. No.	Names of the Companies
1	Aegon Religare Life Insurance Company Limited
2	Religare Enterprises Limited
3	Religare Health Insurance Company Limited
4	Religare Capital Markets Limited

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
1	Religare Health Insurance Company Limited	Audit Committee	Member

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: March 26, 2015

Mr. Mehrotra is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Mr. Mehrotra attended One Board Meeting of the Company.

Mr. Ravi Mehrotra is a Non Executive Director, liable to retire by rotation. Details of remuneration are given under Corporate Governance Report, forming part of Annual Report.

9. Ms. Shradha Suri Marwah

Ms. Shradha Suri Marwah, aged 37 years, is a Post Graduate from The London School of Economics.

She is part of The Suri Group, which has interests in a diverse range of businesses ranging from Automotive Air-conditioner, Hospitality, Precision Component Manufacturing and Telecom to Education.

She is having over 14 years of experience and she is Managing Director of Subros Limited, where she has been a critical part of Change Management and taken the company to new heights. Her key focus areas being creation of a strong R&D, HR, Quality and IT systems enabling decision support.

As a Young Entrepreneur & Visionary Leader, she also drives the Telecom Business of the group where the company (a telecom solutions provider) is engaged in design and manufacturing of access and optical networking equipments.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Ms. Suri holds Directorships:

S. No.	Names of the Companies
1	Rohan Motors Limited
2	Subros Limited
3	Prima Telecom Limited
4	Prima Cellular Limited
5	Fibcom India Limited
6	Uniparts India Limited
7	Denso Subros Thermal Engineering Centre India Limited
8	Asahi India Glass Limited
9	Mercantile Capitals and Financial Services Private Limited
10	Pia Infrastructure Private Limited
11	Prima Infratech Private Limited
12	Automotive Component Manufacturers Association of India

***Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):**

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
NIL			

*Includes only Audit Committee and Shareholder's/Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: March 26, 2015

Ms. Suri is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Ms. Suri attended One Board Meeting of the Company.

Ms. Shradha Suri Marwah is a Non-Executive Independent Director, not liable to retire by rotation. Details of remuneration are given under Report of Corporate Governance, forming part of Annual Report.

10. Mr. Sunil Godhwani

Mr. Sunil Godhwani, aged 54 years, is the Chairman and Managing Director of Religare Enterprises Limited (REL) with over three decades of experience. A man with a vision to create a global business of excellence, he is the inspiration to all as he spearheads REL's management and global operations; strategizing and directing it through its next phase of growth.

Mr. Godhwani brings with him strong leadership skills, vigor and a passion for excellence. He believes in nurturing a culture that is entrepreneurial, result oriented, customer focused and based on teamwork. He has given strategic direction to Religare's growth since his joining in 2001. He has been instrumental in establishing Religare's vast network and shaping the Company's strategies in India and abroad. He is on a constant lookout for taking it to new heights by managing various acquisitions, finding new partners for joint ventures and scouting new avenues for the business. Under his able leadership, Religare Enterprises Limited is India's fastest growing, integrated financial services company with a significant presence in 15 countries across Asia, Africa, Middle East, Europe and the Americas.

He also held the various key positions such as Member of the Economic Policy Council and the Task Force on Indian Financial Markets of the Confederation of Indian Industry (CII), Member of the Executive Committee of the Federation of Indian Chambers of Commerce & Industry (FICCI). He is also a director on the Boards of various Religare group companies.

He has a diverse and wide-ranging experience of over two decades in managing large scale businesses. A powerful orator and a great motivator, he has been awarded with many awards and accolades. In the year 2008, he was awarded with Outlook Money - NDTV Profit Awards 2008' for "Best New IPO Listing" presented by Mr. C.B Bhawe, former Chairman-Securities & Exchange Board of India, in 2009, he was conferred the "CEO of the year" Award at the CEO CLUBS INTERNATIONAL AWARDS, Dubai and 'Udyog Rattan Award' and Religare Enterprises Limited with 'Excellence Award' by Institute of Economic Studies at Indian Habitat Centre, In 2010, he got, 'India Business Leader of the Year' at the Global Indian Business Meeting hosted by Horasis, in Madrid, Spain and also Best M&A Deal in the Health/Life Sciences Category" at the 8th Annual M&A Awards held in New York for the 'Acquisition of strategic stake in Parkway Holdings by Fortis Healthcare Ltd'. He is a prolific writer and speaker at important industry platforms and publications. He continues to play a key role as part of the Indian contingent at the World Economic Forum at Davos. He was speaker at 2010 Buttonwood Gathering held at New York alongside eminent personalities like Vikram Pandit, Stephen Roach and Wilbur L. Ross Jr. also featured in The Economic Times, India's largest business daily, as one of the key people to watch out for in the BFSI space.

Born in New Delhi, he completed his schooling from prestigious St. Columba's School post which he went abroad for studying. He holds a B. Sc. Degree in Chemical Engineering and a M.Sc. in Industrial Engineering & Finance from Polytechnic Institute of New York.

Companies (other than Fortis Healthcare Limited, Foreign Companies and Section 8 Companies) in which Mr. Godhwani holds Directorships:

S. No.	Names of the Companies
1	Religare Commodities Limited
2	Religare Enterprises Limited
3	Religare Health Insurance Company Limited
4	Ligare Voyages Limited
5	SRL Limited
6	Religare Capital Markets Limited
7	Religare Invesco Trustee Company Private Limited
8	IBOF Investment Management Private Limited

*Details of Membership in Committees of other Companies (excluding Private Companies, Foreign Companies and Section 8 Companies):

S. No	Name of Company	Name of Committee	Designation (Chairman/Member)
1	SRL Limited	Share Allotment and Shareholders' Investors' Grievance Committee	Chairman
2	Religare Health Insurance Company Limited	Audit Committee	Member
		Allotment Committee	Chairman
3	Religare Enterprises Limited	Audit Committee	Member
		Stakeholders Relationship Committee	Member

*Includes only Audit Committee and Shareholder's/ Investor Grievance Committee

Shareholding in the Company: NIL.

Original date of appointment: February 26, 2009

Mr. Sunil Godhwani is not related to any Director/Key Managerial Personnel of the Company.

During the Financial Year 2014-15, Mr. Godhwani attended Four Board Meetings of the Company.

Mr. Sunil Godhwani is a Non-Executive Director, liable to retire by rotation. Details of remuneration are given under Report of Corporate Governance, forming part of Annual Report.

**By Order of the Board
For Fortis Healthcare Limited**

**Date : August 6, 2015
Place : Gurgaon**

**Sd/-
Rahul Ranjan
Company Secretary**

Location Map of venue for Nineteenth Annual General Meeting

Day : Wednesday
 Date : September 23, 2015
 Time : 12:00 Hours
 Venue : PHD Chamber of Commerce and Industry,
 4/2 Siri Institutional Area, August Kranti Marg, New Delhi – 110016

